Suppr超能文献

[ETICS研究:特发性慢性呃逆的经验性治疗]

[ETICS Study: Empirical therapy of idiopathic chronic singultus].

作者信息

Petroianu G, Hein G, Petroianu A, Bergler W, Rüfer R

机构信息

Institut für Pharmakologie und Toxikologie, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg.

出版信息

Z Gastroenterol. 1998 Jul;36(7):559-66.

PMID:9738303
Abstract

Idiopathic chronic singultus (ICS) describes recurring episodes of persistent hiccuping lasting longer than an arbitrary time limit (e.g. one month) for which no organic cause or consistently effective treatment can be found. It has been suggested that ICS may result from chronic stimulation of a supraspinal "hiccup center" by impulses originating from receptors in the gastrointestinaltract. This hypotesis implies the possibility of treating ICS by reducing gastric acid (via omeprazole), facilitating gastric emptying (via cisapride), or suppressing of the "hiccup centre" (via GABA-ergic offects of baclofen or gabapentin). 29 patients (28 male, one female; age 71 +/- 10 years) suffering from ICS for four to 564 months were treated with a combination of cisapride (30 mg/d), omeprazole (20 mg/d) and baclofen (45 mg/d) (COB). The patients rated the severity of hiccuping on a subjective assessment scale (SAS) that ranged from 0 (= no hiccuping) to 10 (= unbearable hiccuping). Hiccuping ceased in 38% (11/29) of the treated patients and decreased in severity in an additional 24% (7/29). Mean SAS-scores following 20 to 24 weeks of therapy (3.7 +/- 3.4) were significantly lower compared to before therapy (8.8 +/- 1.3) (Mann-Whitney rank order test [p < 0.02]). In the patients that failed to respond to COB, gabapentin (1.200 mg/d) was substituted for baclofen. Hiccuping ceased in one and improved in two of these ten subjects. We conclude that COB is an effective empirical therapy in the majority of patients with ICS. It may be useful to substitute gabapentin for baclofen in those not responding to COB.

摘要

特发性慢性呃逆(ICS)指持续性呃逆反复发作,持续时间超过一个任意设定的时限(如一个月),且找不到器质性病因或始终有效的治疗方法。有人提出,ICS可能是胃肠道感受器产生的冲动对脊髓上“呃逆中枢”进行慢性刺激所致。这一假说意味着可通过降低胃酸(使用奥美拉唑)、促进胃排空(使用西沙必利)或抑制“呃逆中枢”(使用巴氯芬或加巴喷丁的GABA能效应)来治疗ICS。29例(28例男性,1例女性;年龄71±10岁)患有ICS 4至564个月的患者接受了西沙必利(30毫克/天)、奥美拉唑(20毫克/天)和巴氯芬(45毫克/天)联合治疗(COB)。患者通过主观评估量表(SAS)对呃逆严重程度进行评分,该量表范围为0(=无呃逆)至10(=难以忍受的呃逆)。38%(11/29)的治疗患者呃逆停止,另有24%(7/29)的患者呃逆严重程度减轻。治疗20至24周后的平均SAS评分(3.7±3.4)显著低于治疗前(8.8±1.3)(曼-惠特尼秩和检验[p<0.02])。对COB治疗无反应的患者,用加巴喷丁(1200毫克/天)替代巴氯芬。这10名受试者中有1名呃逆停止,2名有所改善。我们得出结论,COB对大多数ICS患者是一种有效的经验性治疗方法。对于对COB无反应的患者,用加巴喷丁替代巴氯芬可能有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验